Charles S. Lieber, M.D. (1931–2009)
Steven Schenker – 28 May 2009
Cost‐effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
Robert P. Myers, James C. Gregor, Paul J. Marotta – 21 May 2009
Role of cyanoacrylate in the management of bleeding gastric varices
Akio Matsumoto, Hisashi Matsumoto, Hideto Inokuchi – 21 May 2009
Brain edema in liver failure: Basic physiologic principles and management
Fin Stolze Larsen, Julia Wendon – 6 May 2009 – In patients with severe liver failure, brain edema is a frequent and serious complication that may result in high intracranial pressure and brain damage. This short article focuses on basic physiologic principles that determine water flux across the blood‐brain barrier. Using the Starling equation, it is evident that both the osmotic and hydrostatic pressure gradients are imbalanced across the blood‐brain barrier in patients with acute liver failure. This combination will tend to favor cerebral capillary water influx to the brain.
Adipocyte‐hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease
Briohny Smith, Jacob George – 28 April 2009
Closing the gap: The tight junction protein occludin and hepatitis C virus entry
Nicholas S. Eyre, Thomas F. Baumert, Michael R. Beard – 28 April 2009
The structure behind diversity: Covariance networks in hepatitis C virus sequences are associated with treatment response
Jacob Nattermann, Frank Tacke – 28 April 2009
Golgi protein 73 as a biomarker of hepatocellular cancer: Development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies
Claus J. Fimmel, Lorinda Wright – 28 April 2009
Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients
Paolo Muratori, Alessandro Granito, Georgios Pappas, Luigi Muratori – 28 April 2009
Efficacy of hepatitis B vaccine against antiviral drug‐resistant hepatitis B virus mutants in the chimpanzee model
Saleem Kamili, Vitini Sozzi, Geoff Thompson, Katie Campbell, Christopher M. Walker, Stephen Locarnini, Krzysztof Krawczynski – 27 April 2009 – Hepatitis B virus (HBV) mutants resistant to treatment with nucleoside or nucleotide analogs and those with the ability to escape from HBV‐neutralizing antibody have the potential to infect HBV‐vaccinated individuals. To address this potential serious public health challenge, we tested the efficacy of immunity induced by a commercial hepatitis B vaccine against a tissue culture‐derived, clonal HBV polymerase mutant in HBV seronegative chimpanzees.